Profile

PhD, Stony Brook University



Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Kim E, Zucconi BE, Wu M, Nocco SE, Meyers DJ, McGee JS, Venkatesh S, Cohen DL, Gonzalez EC, Ryu B, Cole PA, Alani RM. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma. Cancer Res. 2019 05 15; 79(10):2649-2661.View Related Profiles. PMID: 30910803; PMCID: PMC6522293; DOI: 10.1158/0008-5472.CAN-18-2331;
     
  2. Eisenstein A, Gonzalez EC, Raghunathan R, Xu X, Wu M, McLean EO, McGee J, Ryu B, Alani RM. Emerging Biomarkers in Cutaneous Melanoma. Mol Diagn Ther. 2018 04; 22(2):203-218.View Related Profiles. PMID: 29411301
     
  3. Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018 01 04; 9(1):53.View Related Profiles. PMID: 29302039; PMCID: PMC5754352; DOI: 10.1038/s41467-017-02242-4;
     
  4. Eisenstein A, Chen E, Raghunathan R, Xu X, Wu M, McLean M, McGee J, Ryu B, Alani RM. Emerging Biomarkers in Cutaneous Melanoma. Molecular Diagnosis & Therapy. 2018.
  5. Kalin J, Wu M, Gomez A, Hayward D, Adejola N, Wang L, Roberts J, Prusevich P, Hancock WW, Bradner JE, Mai A, Anders NM, Rudek MA, Ryu B, Alani RM, Mattevi A, Cole PA. CoREST in Peace: Dual Action Inhibitors of Histone Deacetylase and Lysine Specific Demethylase. The FASEB Journal. 2015; 29(1:723.8).
  6. Magri L, Gacias M, Wu M, Swiss VA, Janssen WG, Casaccia P. c-Myc-dependent transcriptional regulation of cell cycle and nucleosomal histones during oligodendrocyte differentiation. Neuroscience. 2014 Sep 12; 276:72-86. PMID: 24502923; PMCID: PMC4294794; DOI: 10.1016/j.neuroscience.2014.01.051;
     
  7. Wu M, Hernandez M, Shen S, Sabo JK, Kelkar D, Wang J, O'Leary R, Phillips GR, Cate HS, Casaccia P. Differential modulation of the oligodendrocyte transcriptome by sonic hedgehog and bone morphogenetic protein 4 via opposing effects on histone acetylation. J Neurosci. 2012 May 09; 32(19):6651-64. PMID: 22573687; PMCID: PMC3412138; DOI: 10.1523/JNEUROSCI.4876-11.2012;
     
  8. Wu M, Nissen JC, Chen EI, Tsirka SE. Tuftsin promotes an anti-inflammatory switch and attenuates symptoms in experimental autoimmune encephalomyelitis. PLoS One. 2012; 7(4):e34933. PMID: 22529957; PMCID: PMC3328491; DOI: 10.1371/journal.pone.0034933;
     
  9. Wu M, Tsirka SE. Endothelial NOS-deficient mice reveal dual roles for nitric oxide during experimental autoimmune encephalomyelitis. Glia. 2009 Aug 15; 57(11):1204-15. PMID: 19170181; PMCID: PMC2706940; DOI: 10.1002/glia.20842;
     
  10. Bhasin M, Wu M, Tsirka SE. Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis. BMC Immunol. 2007 Jul 16; 8:10. PMID: 17634104; PMCID: PMC1937009; DOI: 10.1186/1471-2172-8-10;
     
Showing 10 of 11 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 2 publications over 2 distinct years, with a maximum of 1 publications in 2015 and 2018

YearPublications
20151
20181

Contact for Mentoring: